[{"id":"6a10d540-3227-4566-8606-34570d8b161e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04580485","created_at":"2021-02-24T11:03:20.215Z","updated_at":"2025-02-25T14:07:56.143Z","phase":"Phase 1","brief_title":"INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors","source_id_and_acronym":"NCT04580485","lead_sponsor":"Incyte Corporation","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB106385"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 02/03/2021","start_date":" 02/03/2021","primary_txt":" Primary completion: 01/22/2024","primary_completion_date":" 01/22/2024","study_txt":" Completion: 01/22/2024","study_completion_date":" 01/22/2024","last_update_posted":"2025-02-18"},{"id":"e29e6931-dd47-4e5b-8bd2-f24887bb0bf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06116786","created_at":"2023-11-03T20:12:34.096Z","updated_at":"2025-02-25T14:18:28.129Z","phase":"Phase 1","brief_title":"A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT06116786","lead_sponsor":"Johnson \u0026 Johnson Enterprise Innovation Inc.","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cetrelimab (JNJ-63723283)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 04/14/2027","primary_completion_date":" 04/14/2027","study_txt":" Completion: 06/07/2029","study_completion_date":" 06/07/2029","last_update_posted":"2025-02-17"},{"id":"3aa72670-9b0b-4205-9807-1cc48204caf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05335941","created_at":"2022-04-20T16:53:38.622Z","updated_at":"2025-02-25T15:35:35.713Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma","source_id_and_acronym":"NCT05335941","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MTAP • IL17A","pipe":"","alterations":" ","tags":["MTAP • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-10"},{"id":"15f2feeb-91bd-4d1e-8210-eb0dea4872da","acronym":"ARC-7","url":"https://clinicaltrials.gov/study/NCT04262856","created_at":"2021-01-18T20:42:57.527Z","updated_at":"2024-07-02T16:35:00.997Z","phase":"Phase 2","brief_title":"Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04262856 - ARC-7","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928) • mitazalimab (ADC-1013)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 05/28/2020","start_date":" 05/28/2020","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-24"},{"id":"409dc71f-d788-44b0-9225-6f9acd37a635","acronym":"ARC-4","url":"https://clinicaltrials.gov/study/NCT03846310","created_at":"2021-01-18T18:59:18.192Z","updated_at":"2024-07-02T16:35:01.028Z","phase":"Phase 1","brief_title":"A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer","source_id_and_acronym":"NCT03846310 - ARC-4","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-05-24"},{"id":"e5aa0f89-24de-40bf-8a67-186c3db1a88b","acronym":"ARC-2","url":"https://clinicaltrials.gov/study/NCT03719326","created_at":"2021-01-18T18:13:45.819Z","updated_at":"2024-07-02T16:35:01.152Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies","source_id_and_acronym":"NCT03719326 - ARC-2","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • pegylated liposomal doxorubicin • eganelisib (IPI-549) • etrumadenant (AB928) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 10/15/2018","start_date":" 10/15/2018","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/02/2021","study_completion_date":" 07/02/2021","last_update_posted":"2024-05-24"},{"id":"b2d0e16f-9f16-4b18-afd1-1b771c949f14","acronym":"","url":"https://clinicaltrials.gov/study/NCT05955105","created_at":"2024-05-21T20:33:37.710Z","updated_at":"2024-07-02T16:35:02.295Z","phase":"Phase 1/2","brief_title":"A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT05955105","lead_sponsor":"Innolake Biopharm","biomarkers":" PD-L1 • TMB • MSI • CD8 • CD68","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • MSI • CD8 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • ILB-2109"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/25/2023","start_date":" 07/25/2023","primary_txt":" Primary completion: 01/25/2026","primary_completion_date":" 01/25/2026","study_txt":" Completion: 07/24/2026","study_completion_date":" 07/24/2026","last_update_posted":"2024-05-21"},{"id":"f5b1a6c8-e4d4-430b-b708-74c9cb48dc4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04791839","created_at":"2021-03-10T12:55:03.832Z","updated_at":"2024-07-02T16:35:10.680Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04791839","lead_sponsor":"Washington University School of Medicine","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/04/2021","start_date":" 08/04/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2024-04-09"},{"id":"d9e41d11-6531-42e9-b1fb-7da01cc397b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454451","created_at":"2021-01-18T17:02:00.296Z","updated_at":"2024-07-02T16:35:25.568Z","phase":"Phase 1","brief_title":"CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers","source_id_and_acronym":"NCT03454451","lead_sponsor":"Corvus Pharmaceuticals, Inc.","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ciforadenant (CPI-444) • mupadolimab (CPI-006)"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 04/25/2018","start_date":" 04/25/2018","primary_txt":" Primary completion: 12/28/2022","primary_completion_date":" 12/28/2022","study_txt":" Completion: 02/19/2023","study_completion_date":" 02/19/2023","last_update_posted":"2023-12-21"},{"id":"bd4c0ff9-06d4-4a21-b139-a7ee3b5948c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02740985","created_at":"2021-01-18T13:25:31.246Z","updated_at":"2024-07-02T16:35:47.034Z","phase":"Phase 1","brief_title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT02740985","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • docetaxel • Xtandi (enzalutamide) • abiraterone acetate • dexamethasone • oleclumab (MEDI9447) • imaradenant (AZD4635)"],"overall_status":"Completed","enrollment":" Enrollment 313","initiation":"Initiation: 06/17/2016","start_date":" 06/17/2016","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-05-26"},{"id":"f890a20d-bc67-4162-a724-78d3550f47b0","acronym":"AdenONCO","url":"https://clinicaltrials.gov/study/NCT02403193","created_at":"2021-01-18T11:28:24.652Z","updated_at":"2025-02-25T15:42:21.293Z","phase":"Phase 1","brief_title":"Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT02403193 - AdenONCO","lead_sponsor":"Palobiofarma SL","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • taminadenant (NIR178)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 11/24/2021","study_completion_date":" 11/24/2021","last_update_posted":"2022-01-12"}]